Lung Cancer Dispatch
Follow
Find tag "tegafur"
3.7K views | +5 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Combination of S-1, Platinol, and Radiation Promising for Lung Cancer

Combination of S-1, Platinol, and Radiation Promising for Lung Cancer | Lung Cancer Dispatch | Scoop.it

Results from a phase II clinical trial suggest that combining the cancer drug S-1 (Teysuno) with the chemotherapy agent cisplatin (Platinol) and radiation therapy may be effective in non-small cell lung cancer (NSCLC). Patients with inoperable, locally advanced NSCLC were treated with S-1, Platinol, and radiation to the chest region. Tumors shrank at least 30% in 36 out of 41 patients. Although some patients experienced low levels of white blood cells, overall the treatment was well tolerated. S-1 is itself a combination of tegafur (a chemotherapy agent), gimeracil (which boosts tegafur levels in the body), and oteracil (which protects the stomach and gut from tegafur toxicity).

Cancer Commons's insight:

Healio | Nov 8, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Combined Calsed and S-1 May be Effective Second-Line Treatment for Lung Cancer without EGFR Mutations

While new treatments for non-small cell lung cancer (NSCLC) such as tyrosine kinase inhibitors (TKIs) and Alimta (pemetrexed) are effective second-line treatments for patients whose tumors carry mutations in the EGFR gene, they are less effective for patients without such mutations. Twenty-six patients with inoperable, previously treated NSCLC received treatment with amrubicin (Calsed) and S-1 and experienced higher treatment response rates, longer periods without cancer progression, and longer overall survival than has been reported with single-agent chemotherapy. The beneficial effects were independent of cancer subtype, suggesting that combined Calsed and S-1 may be an effective second-line treatment for NSCLC without EGFR mutation.


Research paper: http://link.springer.com/article/10.1007/s00280-012-2061-1/fulltext.html

Cancer Commons's insight:

Cancer Chemotherapy and Pharmacology | Jan 18, 2013

more...
No comment yet.